Literature DB >> 18416461

Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamide-induced cirrhotic rats.

Hao Xu1, Bao-Min Shi, Xiao-Fei Lu, Feng Liang, Xing Jin, Tai-Huang Wu, Jian Xu.   

Abstract

AIM: To investigate the effect of vascular endothelial growth factor (VEGF) transfection on hepatic sinusoidal capillarization.
METHODS: Enhanced green fluorescent protein (EGFP)/VEGF transfection was confirmed by immunofluorescence microscopy and immunohistochemistry both in primary hepatocytes and in normal liver. Cirrhotic rats were generated by thioacetamide (TAA) administration and then divided into a treatment group, which received injections of 400 microg of plasmid DNA encoding an EGFP-VEGF fusion protein, and a blank group, which received an equal amount of normal saline through the portal vein. The portal vein pressure was measured in the normal and cirrhotic state, in treated and blank groups. The average number of fenestrae per hepatic sinusoid was determined using transmission electron microscopy (TEM), while the relative abundance of VEGF transcripts was examined by Gene array.
RESULTS: Green fluorescent protein was observed in the cytoplasms of liver cells under immunofluorescence microscopy 24 h after transfection with EGFP/VEGF plasmid in vitro. Staining with polyclonal antibodies against VEGF illustrated that hepatocytes expressed immunodetectable VEGF both in vitro and in vitro. There were significant differences in the number of fenestrae and portal vein pressures between normal and cirrhotic rats (7.40 +/- 1.71 vs 2.30 +/- 1.16 and 9.32 +/- 0.85 cmH2O vs 17.92 +/- 0.90 cmH2O, P < 0.01), between cirrhotic and treated rats (2.30 +/- 1.16 cmH2O vs 4.60 +/- 1.65 and 17.92 +/- 0.90 cmH2O vs 15.52 +/- 0.93 cmH2O, P < 0.05) and between the treatment group and the blank group (4.60 +/- 1.65 cmH2O vs 2.10 +/- 1.10 cmH2O and 15.52 +/- 0.93 cmH2O vs 17.26 +/- 1.80 cmH2O, P < 0.05). Gene-array analysis revealed that the relative abundance of transcripts of VEGF family members decreased in the cirrhotic state and increased after transfection.
CONCLUSION: Injection of a plasmid encoding VEGF through the portal vein is an effective method to induce the formation of fenestrae and decrease portal vein pressure in cirrhotic rats. Therefore, it may be a good choice for treating hepatic cirrhosis and portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18416461      PMCID: PMC2705089          DOI: 10.3748/wjg.14.2349

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  Vascular endothelial growth factor levels in liver cirrhosis.

Authors:  J Genesca; A González; A Mujal; F Cereto; R Segura
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

2.  Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121.

Authors:  L Y Lee; S R Patel; N R Hackett; C A Mack; D R Polce; T El-Sawy; R Hachamovitch; P Zanzonico; T A Sanborn; M Parikh; O W Isom; R G Crystal; T K Rosengart
Journal:  Ann Thorac Surg       Date:  2000-01       Impact factor: 4.330

3.  Molecular cloning of a novel vascular endothelial growth factor, VEGF-D.

Authors:  Y Yamada; J Nezu; M Shimane; Y Hirata
Journal:  Genomics       Date:  1997-06-15       Impact factor: 5.736

4.  Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo.

Authors:  Tatiana V Byzova; Corey K Goldman; Jurek Jankau; Juhua Chen; Gustavo Cabrera; Marc G Achen; Steven A Stacker; Kevin A Carnevale; Maria Siemionow; Steven R Deitcher; Paul E DiCorleto
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF.

Authors:  Miriam Bueno; Silvia Salgado; Carlos Beas-Zárate; Juan Armendariz-Borunda
Journal:  J Gene Med       Date:  2006-11       Impact factor: 4.565

6.  Recombinant AAV vector encoding human VEGF165 enhances wound healing.

Authors:  B Deodato; N Arsic; L Zentilin; M Galeano; D Santoro; V Torre; D Altavilla; D Valdembri; F Bussolino; F Squadrito; M Giacca
Journal:  Gene Ther       Date:  2002-06       Impact factor: 5.250

7.  Simultaneous transfer of vascular endothelial growth factor and hepatocyte growth factor genes effectively promotes liver regeneration after hepatectomy in cirrhotic rats.

Authors:  Hideaki Oe; Toshimi Kaido; Hiroaki Furuyama; Akira Mori; Masayuki Imamura
Journal:  Hepatogastroenterology       Date:  2004 Nov-Dec

8.  VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells.

Authors:  Jun Chen; Filip Braet; Sergey Brodsky; Talia Weinstein; Victor Romanov; Eisei Noiri; Michael S Goligorsky
Journal:  Am J Physiol Cell Physiol       Date:  2002-05       Impact factor: 4.249

Review 9.  Therapeutic angiogenesis in critical limb and myocardial ischemia.

Authors:  P R Vale; J M Isner; K Rosenfield
Journal:  J Interv Cardiol       Date:  2001-10       Impact factor: 2.279

10.  The new anti-actin agent dihydrohalichondramide reveals fenestrae-forming centers in hepatic endothelial cells.

Authors:  Filip Braet; Ilan Spector; Nava Shochet; Phillip Crews; Tatsuo Higa; Eline Menu; Ronald de Zanger; Eddie Wisse
Journal:  BMC Cell Biol       Date:  2002-03-21       Impact factor: 4.241

View more
  8 in total

1.  Mesenchymal stem cells support hepatocyte function in engineered liver grafts.

Authors:  Yoshie Kadota; Hiroshi Yagi; Kenta Inomata; Kentaro Matsubara; Taizo Hibi; Yuta Abe; Minoru Kitago; Masahiro Shinoda; Hideaki Obara; Osamu Itano; Yuko Kitagawa
Journal:  Organogenesis       Date:  2014-01-31       Impact factor: 2.500

2.  Congenital multiple intrahepatic portosystemic shunt: an autopsy case.

Authors:  Seishiro Takahashi; Eriko Yoshida; Yasushi Sakanishi; Norihiro Tohyama; Ayse Ayhan; Hiroshi Ogawa
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

3.  Cells involved in extracellular matrix remodeling after acute myocardial infarction.

Authors:  Larissa Ferraz Garcia; Fábio D'Aguiar Mataveli; Ana Maria Amaral Antônio Mader; Thérèse Rachell Theodoro; Giselle Zenker Justo; Maria Aparecida da Silva Pinhal
Journal:  Einstein (Sao Paulo)       Date:  2015 Jan-Mar

4.  Collagen-binding vascular endothelial growth factor attenuates CCl4-induced liver fibrosis in mice.

Authors:  Kangkang Wu; Rui Huang; Hongyan Wu; Yong Liu; Chenchen Yang; Shufeng Cao; Xianglin Hou; Bing Chen; Jianwu DaI; Chao Wu
Journal:  Mol Med Rep       Date:  2016-10-12       Impact factor: 2.952

5.  Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice.

Authors:  Ling-Jian Kong; Hao Li; Ya-Ju Du; Feng-Hua Pei; Ying Hu; Liao-Liao Zhao; Jing Chen
Journal:  Mol Med Rep       Date:  2017-03-15       Impact factor: 2.952

Review 6.  Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier.

Authors:  Simon C Satchell; Filip Braet
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-07

7.  Toxic damage increases angiogenesis and metastasis in fibrotic livers via PECAM-1.

Authors:  Esther Raskopf; Maria Angeles Gonzalez Carmona; Christina Jay Van Cayzeele; Christian Strassburg; Tilman Sauerbruch; Volker Schmitz
Journal:  Biomed Res Int       Date:  2014-03-06       Impact factor: 3.411

8.  Carvedilol Ameliorates Intrahepatic Angiogenesis, Sinusoidal Remodeling and Portal Pressure in Cirrhotic Rats.

Authors:  Liping Ling; Guangqi Li; Dongxiao Meng; Sining Wang; Chunqing Zhang
Journal:  Med Sci Monit       Date:  2018-11-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.